Login Register Cart 0
Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Male Breast Cancer: Three Case Reports and a Literature Review

Author(s): Yuanfang Xin, Fengmei Wang, Dengfeng Ren, Fuxing Zhao and Jiuda Zhao*

Volume 23, Issue 19, 2023

Published on: 18 September, 2023

Page: [2161 - 2169] Pages: 9

DOI: 10.2174/1871520623666230821124008

Price: $65

Abstract

Introduction: Male breast cancer (MBC) accounts for 0.5%-1% of all breast cancers diagnosed worldwide. However, its biological characteristics can be distinguished from that of female breast cancer (FBC).

Case Representation: The diagnostic and treatment approaches for MBC are mainly similar to that of FBC due to the lack of male breast cancer-related studies, clinical trials, and literature. An increasing number of retrospective and prospective studies have been conducted to clarify the individualized care for MBC. Herein, we report three cases of advanced MBC to describe the diagnostic approaches, treatment process, and survival prognosis.

Conclusion: MBC patients had older age, later stage at first diagnosis, higher expression of hormone receptors, and poor prognosis. A literature review was conducted to determine the incidence, risk factors, disease features, diagnosis, treatment, survival, and management of MBC.

« Previous
Graphical Abstract

[1]
Reis, L.O.; Dias, F.G.; Castro, M.A.; Ferreira, U. Male breast cancer. Aging Male, 2011, 14(2), 99-109.
[http://dx.doi.org/10.3109/13685538.2010.535048] [PMID: 21204612]
[2]
Abdelwahab Yousef, A.J. Male breast cancer: Epidemiology and risk factors. Semin. Oncol., 2017, 44(4), 267-272.
[http://dx.doi.org/10.1053/j.seminoncol.2017.11.002] [PMID: 29526255]
[3]
Gucalp, A.; Traina, T.A.; Eisner, J.R.; Parker, J.S.; Selitsky, S.R.; Park, B.H.; Elias, A.D.; Baskin-Bey, E.S.; Cardoso, F. Male breast cancer: A disease distinct from female breast cancer. Breast Cancer Res. Treat., 2019, 173(1), 37-48.
[http://dx.doi.org/10.1007/s10549-018-4921-9] [PMID: 30267249]
[4]
Comparison between male and female breast cancer survival using propensity score matching analysis. Available From: https://pubmed.ncbi.nlm.nih.gov/34079019/ (Accessed May 16 2022)
[5]
Elbachiri, M.; Fatima, S.; Bouchbika, Z.; Benchekroun, N.; Jouhadi, H.; Tawfiq, N.; Sahraoui, S.; Benider, A. Breast cancer in men: About 40 cases and literature review. Pan Afr. Med. J., 2017, 28, 287.
[http://dx.doi.org/10.11604/pamj.2017.28.287.13527] [PMID: 29675121]
[6]
Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin., 2021, 71(1), 7-33.
[http://dx.doi.org/10.3322/caac.21654] [PMID: 33433946]
[7]
Leon-Ferre, R.A.; Giridhar, K.V.; Hieken, T.J.; Mutter, R.W.; Couch, F.J.; Jimenez, R.E.; Hawse, J.R.; Boughey, J.C.; Ruddy, K.J. A contemporary review of male breast cancer: Current evidence and unanswered questions. Cancer Metastasis Rev., 2018, 37(4), 599-614.
[http://dx.doi.org/10.1007/s10555-018-9761-x] [PMID: 30232577]
[8]
Darkeh, M.H.S.E.; Azavedo, E. Male breast cancer clinical features, risk factors, and current diagnostic and therapeutic approaches. Int. J. Clin. Med., 2014, 5(17), 1068-1086.
[http://dx.doi.org/10.4236/ijcm.2014.517138]
[9]
Anderson, W.F.; Jatoi, I.; Tse, J.; Rosenberg, P.S. Male breast cancer: A population-based comparison with female breast cancer. J. Clin. Oncol., 2010, 28(2), 232-239.
[http://dx.doi.org/10.1200/JCO.2009.23.8162] [PMID: 19996029]
[10]
Miao, H.; Verkooijen, H.M.; Chia, K.S.; Bouchardy, C.; Pukkala, E.; Larønningen, S.; Mellemkjær, L.; Czene, K.; Hartman, M. Incidence and outcome of male breast cancer: An international population-based study. J. Clin. Oncol., 2011, 29(33), 4381-4386.
[http://dx.doi.org/10.1200/JCO.2011.36.8902] [PMID: 21969512]
[11]
Scott-Conner, C.E.H.; Jochimsen, P.R.; Menck, H.R.; Winchester, D.J. An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients. Surgery, 1999, 126(4), 775-781.
[http://dx.doi.org/10.1016/S0039-6060(99)70135-2] [PMID: 10520928]
[12]
Yalaza, M.; İnan, A.; Bozer, M. Male breast cancer. J. Breast Health, 2016, 12(1), 1-8.
[http://dx.doi.org/10.5152/tjbh.2015.2711] [PMID: 28331724]
[13]
Fentiman, I.S.; Fourquet, A.; Hortobagyi, G.N. Male breast cancer. Lancet, 2006, 367(9510), 595-604.
[http://dx.doi.org/10.1016/S0140-6736(06)68226-3] [PMID: 16488803]
[14]
Is male breast cancer similar or different than female breast cancer? Available From: https://pubmed.ncbi.nlm.nih.gov/14997057/ (Accessed November 18 2021)
[15]
Agrawal, A.; Ayantunde, A.A.; Rampaul, R.; Robertson, J.F.R. Male breast cancer: A review of clinical management. Breast Cancer Res. Treat., 2007, 103(1), 11-21.
[http://dx.doi.org/10.1007/s10549-006-9356-z] [PMID: 17033919]
[16]
Giordano, S.H. Breast cancer in men. N. Engl. J. Med., 2018, 378(24), 2311-2320.
[http://dx.doi.org/10.1056/NEJMra1707939] [PMID: 29897847]
[17]
Antoniou, A.; Pharoah, P.D.P.; Narod, S.; Risch, H.A.; Eyfjord, J.E.; Hopper, J.L.; Loman, N.; Olsson, H.; Johannsson, O.; Borg, Å.; Pasini, B.; Radice, P.; Manoukian, S.; Eccles, D.M.; Tang, N.; Olah, E.; Anton-Culver, H.; Warner, E.; Lubinski, J.; Gronwald, J.; Gorski, B.; Tulinius, H.; Thorlacius, S.; Eerola, H.; Nevanlinna, H.; Syrjäkoski, K.; Kallioniemi, O.P.; Thompson, D.; Evans, C.; Peto, J.; Lalloo, F.; Evans, D.G.; Easton, D.F. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet., 2003, 72(5), 1117-1130.
[http://dx.doi.org/10.1086/375033] [PMID: 12677558]
[18]
Balcı, A.; Huusko, P.; Pääkkönen, K.; Launonen, V.; Üner, A.; Ekmekçi, A.; Winqvist, R. Mutation analysis of BRCA1 and BRCA2 in Turkish cancer families: A novel mutation BRCA2 3414del4 found in male breast cancer. Eur. J. Cancer, 1999, 35(5), 707-710.
[http://dx.doi.org/10.1016/S0959-8049(99)00014-3] [PMID: 10505028]
[19]
Ottini, L.; Masala, G.; D’Amico, C.; Mancini, B.; Saieva, C.; Aceto, G.; Gestri, D.; Vezzosi, V.; Falchetti, M.; De Marco, M.; Paglierani, M.; Cama, A.; Bianchi, S.; Mariani-Costantini, R.; Palli, D. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: A population-based study in Italy. Cancer Res., 2003, 63(2), 342-347.
[PMID: 12543786]
[20]
Basham, V.M.; Lipscombe, J.M.; Ward, J.M.; Gayther, S.A.; Ponder, B.A.J.; Easton, D.F.; Pharoah, P.D.P. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res., 2001, 4(1), R2.
[http://dx.doi.org/10.1186/bcr419] [PMID: 11879560]
[21]
Lenfant-Pejovic, M.H.; Mlika-Cabanne, N.; Bouchardy, C.; Auquier, A. Risk factors for male breast cancer: A Franco-Swiss case-control study. Int. J. Cancer, 1990, 45(4), 661-665.
[http://dx.doi.org/10.1002/ijc.2910450415] [PMID: 2323842]
[22]
Olsson, H.; Ranstam, J. Head trauma and exposure to prolactin-elevating drugs as risk factors for male breast cancer. J. Natl. Cancer Inst., 1988, 80(9), 679-683.
[http://dx.doi.org/10.1093/jnci/80.9.679] [PMID: 3373557]
[23]
De Los Santos, J.F.; Buchholz, T.A. Carcinoma of the male breast. Curr. Treat. Options Oncol., 2000, 1(3), 221-227.
[http://dx.doi.org/10.1007/s11864-000-0033-x] [PMID: 12057164]
[24]
Lowell, D.M.; Martineau, R.G.; Luria, S.B. Carcinoma of the male breast following radiation. Report of a case occurring 35 years after radiation therapy of unilateral prepubertal gynecomastia. Cancer, 1968, 22(3), 581-586.
[http://dx.doi.org/10.1002/1097-0142(196809)22:3<581:AID-CNCR2820220314>3.0.CO;2-N] [PMID: 4299779]
[25]
Sasco, A.J.; Lowenfels, A.B.; Jong, P.P-D. Review article: Epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int. J. Cancer, 1993, 53(4), 538-549.
[http://dx.doi.org/10.1002/ijc.2910530403] [PMID: 8436428]
[26]
Ron, E.; Ikeda, T.; Preston, D.L.; Tokuoka, S. Male breast cancer incidence among atomic bomb survivors. J. Natl. Cancer Inst., 2005, 97(8), 603-605.
[http://dx.doi.org/10.1093/jnci/dji097] [PMID: 15840883]
[27]
Little, M.P.; McElvenny, D.M. Male breast cancer incidence and mortality risk in the japanese atomic bomb survivors: Differences in excess relative and absolute risk from female breast cancer. Environ. Health Perspect., 2017, 125(2), 223-229.
[http://dx.doi.org/10.1289/EHP151] [PMID: 27286002]
[28]
Brainard, G.C.; Kavet, R.; Kheifets, L.I. The relationship between electromagnetic field and light exposures to melatonin and breast cancer risk: A review of the relevant literature. J. Pineal Res., 1999, 26(2), 65-100.
[http://dx.doi.org/10.1111/j.1600-079X.1999.tb00568.x] [PMID: 10100735]
[29]
Stenlund, C.; Floderus, B. Occupational exposure to magnetic fields in relation to male breast cancer and testicular cancer: A Swedish case-control study. Cancer Causes Control, 1997, 8(2), 184-191.
[http://dx.doi.org/10.1023/A:1018468112964] [PMID: 9134242]
[30]
Rosenbaum, P.F.; Vena, J.E.; Zielezny, M.A.; Michalek, A.M. Occupational exposures associated with male breast cancer. Am. J. Epidemiol., 1994, 139(1), 30-36.
[http://dx.doi.org/10.1093/oxfordjournals.aje.a116932] [PMID: 8296772]
[31]
Sun, J.W.; Li, X.R.; Gao, H.Y.; Yin, J.Y.; Qin, Q.; Nie, S.F.; Wei, S. Electromagnetic field exposure and male breast cancer risk: A meta-analysis of 18 studies. Asian Pac. J. Cancer Prev., 2013, 14(1), 523-528.
[http://dx.doi.org/10.7314/APJCP.2013.14.1.523] [PMID: 23534787]
[32]
Hansen, J. Elevated risk for male breast cancer after occupational exposure to gasoline and vehicular combustion products. Am. J. Ind. Med., 2000, 37(4), 349-352.
[http://dx.doi.org/10.1002/(SICI)1097-0274(200004)37:4<349:AID-AJIM4>3.0.CO;2-L] [PMID: 10706746]
[33]
Laouali, N.; Pilorget, C.; Cyr, D.; Neri, M.; Kaerlev, L.; Sabroe, S.; Gorini, G.; Richiardi, L.; Morales-Suárez-Varela, M.; Llopis-Gonzalez, A.; Ahrens, W.; Jöckel, K.H.; Afonso, N.; Eriksson, M.; Merletti, E.; Olsen, J.; Lynge, E.; Guénel, P. Occupational exposure to organic solvents and risk of male breast cancer: A European multicenter case-control study. Scand. J. Work Environ. Health, 2018, 44(3), 310-322.
[http://dx.doi.org/10.5271/sjweh.3717] [PMID: 29405242]
[34]
Brinton, L.A.; Key, T.J.; Kolonel, L.N.; Michels, K.B.; Sesso, H.D.; Ursin, G.; Van Den Eeden, S.K.; Wood, S.N.; Falk, R.T.; Parisi, D.; Guillemette, C.; Caron, P.; Turcotte, V.; Habel, L.A.; Isaacs, C.J.; Riboli, E.; Weiderpass, E.; Cook, M.B. Prediagnostic sex steroid hormones in relation to male breast cancer risk. J. Clin. Oncol., 2015, 33(18), 2041-2050.
[http://dx.doi.org/10.1200/JCO.2014.59.1602] [PMID: 25964249]
[35]
Hultborn, R.; Hanson, C.; Köpf, I.; Verbiené, I.; Warnhammar, E.; Weimarck, A. Prevalence of Klinefelter’s syndrome in male breast cancer patients. Anticancer Res., 1997, 17(6D), 4293-4297.
[PMID: 9494523]
[36]
Ruddy, K.J.; Winer, E.P. Male breast cancer: Risk factors, biology, diagnosis, treatment, and survivorship. Ann. Oncol., 2013, 24(6), 1434-1443.
[http://dx.doi.org/10.1093/annonc/mdt025] [PMID: 23425944]
[37]
Giordano, S.H.; Cohen, D.S.; Buzdar, A.U.; Perkins, G.; Hortobagyi, G.N. Breast carcinoma in men. Cancer, 2004, 101(1), 51-57.
[http://dx.doi.org/10.1002/cncr.20312] [PMID: 15221988]
[38]
Chavez-MacGregor, M.; Clarke, C.A.; Lichtensztajn, D.; Hortobagyi, G.N.; Giordano, S.H. Male breast cancer according to tumor subtype and race. Cancer, 2013, 119(9), 1611-1617.
[http://dx.doi.org/10.1002/cncr.27905] [PMID: 23341341]
[39]
Cardoso, F.; Bartlett, J.M.S.; Slaets, L.; van Deurzen, C.H.M.; van Leeuwen-Stok, E.; Porter, P.; Linderholm, B.; Hedenfalk, I.; Schröder, C.; Martens, J.; Bayani, J.; van Asperen, C.; Murray, M.; Hudis, C.; Middleton, L.; Vermeij, J.; Punie, K.; Fraser, J.; Nowaczyk, M.; Rubio, I.T.; Aebi, S.; Kelly, C.; Ruddy, K.J.; Winer, E.; Nilsson, C.; Lago, L.D.; Korde, L.; Benstead, K.; Bogler, O.; Goulioti, T.; Peric, A.; Litière, S.; Aalders, K.C.; Poncet, C.; Tryfonidis, K.; Giordano, S.H. Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann. Oncol., 2018, 29(2), 405-417.
[http://dx.doi.org/10.1093/annonc/mdx651] [PMID: 29092024]
[40]
Bagchi, S. Men with breast cancer have high risk of second cancer. Lancet Oncol., 2007, 8(3), 198.
[http://dx.doi.org/10.1016/S1470-2045(07)70067-0] [PMID: 17348113]
[41]
Dong, C.; Hemminki, K. Second primary breast cancer in men. Breast Cancer Res. Treat., 2001, 66(2), 171-172.
[http://dx.doi.org/10.1023/A:1010639429207] [PMID: 11437104]
[42]
Mathew, J.; Perkins, G.H.; Stephens, T.; Middleton, L.P.; Yang, W.T. Primary breast cancer in men: clinical, imaging, and pathologic findings in 57 patients. AJR Am. J. Roentgenol., 2008, 191(6), 1631-1639.
[http://dx.doi.org/10.2214/AJR.08.1076] [PMID: 19020230]
[43]
Draghi, F.; Tarantino, C.C.; Madonia, L.; Ferrozzi, G. Ultrasonography of the male breast. J. Ultrasound, 2011, 14(3), 122-129.
[http://dx.doi.org/10.1016/j.jus.2011.06.004] [PMID: 23397020]
[44]
Yitta, S.; Singer, C.I.; Toth, H.B.; Mercado, C.L. Image presentation. Sonographic appearances of benign and malignant male breast disease with mammographic and pathologic correlation. J. Ultrasound Med., 2010, 29(6), 931-947.
[http://dx.doi.org/10.7863/jum.2010.29.6.931] [PMID: 20498468]
[45]
Sneige, N.; Holder, P.D.; Katz, R.L.; Fanning, C.V.; Dekmezian, R.H.; Shabb, N.S.; Singletary, S.E. Fine-needle aspiration cytology of the male breast in a cancer center. Diagn. Cytopathol., 1993, 9(6), 691-697.
[http://dx.doi.org/10.1002/dc.2840090619] [PMID: 8143548]
[46]
Hoda, R.S.; Arpin, R.N., III; Gottumukkala, R.V.; Hughes, K.S.; Ly, A.; Brachtel, E.F. Diagnostic value of fine-needle aspiration in male breast lesions. Acta Cytol., 2019, 63(4), 319-327.
[http://dx.doi.org/10.1159/000494486] [PMID: 30904908]
[47]
Yang, Y.; Li, S.; Liu, G.; Shao, Z. Is core needle biopsy effective at diagnosing male breast lesions? Breast Cancer Res. Treat., 2019, 177(2), 507-511.
[http://dx.doi.org/10.1007/s10549-019-05312-x] [PMID: 31168757]
[48]
Massarweh, S.A.; Sledge, G.W.; Miller, D.P.; McCullough, D.; Petkov, V.I.; Shak, S. Molecular characterization and mortality from breast cancer in men. J. Clin. Oncol., 2018, 36(14), 1396-1404.
[http://dx.doi.org/10.1200/JCO.2017.76.8861] [PMID: 29584547]
[49]
Turashvili, G.; Gonzalez-Loperena, M.; Brogi, E.; Dickler, M.; Norton, L.; Morrow, M.; Wen, H.Y. The 21-gene recurrence score in male breast cancer. Ann. Surg. Oncol., 2018, 25(6), 1530-1535.
[http://dx.doi.org/10.1245/s10434-018-6411-z] [PMID: 29520654]
[50]
Grenader, T.; Yerushalmi, R.; Tokar, M.; Fried, G.; Kaufman, B.; Peretz, T.; Geffen, D.B. The 21-gene recurrence score assay (Oncotype DX™) in estrogen receptor-positive male breast cancer: Experience in an Israeli cohort. Oncology, 2014, 87(1), 1-6.
[http://dx.doi.org/10.1159/000360793] [PMID: 24970679]
[51]
La Pinta, M.; Fabi, A.; Ascarelli, A.; Ponzani, T.; Di Carlo, V.; Scicchitano, F.; Saputo, S.; Russillo, M.; Andrich, R. Male breast cancer: 6-year experience. Minerva Chir., 2008, 63(2), 71-78.
[PMID: 18427439]
[52]
Lin, A.P.; Huang, T.W.; Tam, K.W. Treatment of male breast cancer: meta-analysis of real-world evidence. Br. J. Surg., 2021, 108(9), 1034-1042.
[http://dx.doi.org/10.1093/bjs/znab279] [PMID: 34476472]
[53]
Yadav, S.; Karam, D.; Bin Riaz, I.; Xie, H.; Durani, U.; Duma, N.; Giridhar, K.V.; Hieken, T.J.; Boughey, J.C.; Mutter, R.W.; Hawse, J.R.; Jimenez, R.E.; Couch, F.J.; Leon-Ferre, R.A.; Ruddy, K.J. Male breast cancer in the united states: Treatment patterns and prognostic fac-tors in the 21st century. Cancer, 2020, 126(1), 26-36.
[http://dx.doi.org/10.1002/cncr.32472] [PMID: 31588557]
[54]
Rogowski, P.; Schönecker, S.; Pazos, M.; Reitz, D.; Braun, M.; Pölcher, M.; Hanusch, C.; Wuerstlein, R.; Harbeck, N.; Mahner, S.; Belka, C.; Corradini, S. Pattern of care of adjuvant radiotherapy in male breast cancer patients in clinical practice: An observational study. Strahlenther. Onkol., 2019, 195(4), 289-296.
[http://dx.doi.org/10.1007/s00066-018-1337-8] [PMID: 30046931]
[55]
Jardel, P.; Vignot, S.; Cutuli, B.; Creisson, A.; Vass, S.; Barranger, E.; Thariat, J. Should adjuvant radiation therapy be systematically pro-posed for male breast cancer? a systematic review. Anticancer Res., 2018, 38(1), 23-31.
[http://dx.doi.org/10.21873/anticanres.12187] [PMID: 29277752]
[56]
Onkologie, L. S3-leitlinie früherkennung, diagnose, therapie und nachsorge des mammakarzinoms, version 4.0, 2017 AWMF register-nummer: 032-045OL. Retrieved, 2018, 28, 198-201.
[57]
Gennari, R.; Curigliano, G.; Jereczek-Fossa, B.; Zurrida, S.; Renne, G.; Intra, M.; Galimberti, V.; Luini, A.; Orecchia, R.; Viale, G.; Gold-hrisch, A.; Veronesi, U. Male breast cancer: A special therapeutic problem. Anything new? (Review). Int. J. Oncol., 2004, 24(3), 663-670.
[http://dx.doi.org/10.3892/ijo.24.3.663] [PMID: 14767551]
[58]
Korde, L.A.; Zujewski, J.A.; Kamin, L.; Giordano, S.; Domchek, S.; Anderson, W.F.; Bartlett, J.M.S.; Gelmon, K.; Nahleh, Z.; Bergh, J.; Cutuli, B.; Pruneri, G.; McCaskill-Stevens, W.; Gralow, J.; Hortobagyi, G.; Cardoso, F. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J. Clin. Oncol., 2010, 28(12), 2114-2122.
[http://dx.doi.org/10.1200/JCO.2009.25.5729] [PMID: 20308661]
[59]
Yu, X.F.; Wang, C.; Chen, B.; Liang, C.; Chen, D.; Yu, Y.; Yang, H. The effect of adjuvant chemotherapy in male breast cancer: 134 Cases from a retrospective study. ESMO Open, 2017, 2(2), e000134.
[http://dx.doi.org/10.1136/esmoopen-2016-000134] [PMID: 28761739]
[60]
Bagley, C.S.; Wesley, M.N.; Young, R.C.; Lippman, M.E. Adjuvant chemotherapy in males with cancer of the breast. Am. J. Clin. Oncol., 1987, 10(1), 55-60.
[http://dx.doi.org/10.1097/00000421-198702000-00013] [PMID: 3825994]
[61]
Walshe, J.M.; Berman, A.W.; Vatas, U.; Steinberg, S.M.; Anderson, W.F.; Lippman, M.E.; Swain, S.M. A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up. Breast Cancer Res. Treat., 2007, 103(2), 177-183.
[http://dx.doi.org/10.1007/s10549-006-9363-0] [PMID: 17039267]
[62]
Li, W.P.; Gao, H.F.; Ji, F.; Zhu, T.; Cheng, M.Y.; Yang, M.; Yang, C.Q.; Zhang, L.L.; Li, J.Q.; Zhang, J.S.; Wang, K. The role of adjuvant chemotherapy in stage I-III male breast cancer: A SEER-based analysis. Ther. Adv. Med. Oncol., 2020, 12.
[http://dx.doi.org/10.1177/1758835920958358] [PMID: 33014148]
[63]
Hassett, M.J.; Somerfield, M.R.; Baker, E.R.; Cardoso, F.; Kansal, K.J.; Kwait, D.C.; Plichta, J.K.; Ricker, C.; Roshal, A.; Ruddy, K.J.; Safer, J.D.; Van Poznak, C.; Yung, R.L.; Giordano, S.H. Management of male breast cancer: ASCO guideline. J. Clin. Oncol., 2020, 38(16), 1849-1863.
[http://dx.doi.org/10.1200/JCO.19.03120] [PMID: 32058842]
[64]
Eggemann, H.; Brucker, C.; Schrauder, M.; Thill, M.; Flock, F.; Reinisch, M.; Costa, S.D.; Ignatov, A. Survival benefit of tamoxifen in male breast cancer: Prospective cohort analysis. Br. J. Cancer, 2020, 123(1), 33-37.
[http://dx.doi.org/10.1038/s41416-020-0857-z] [PMID: 32367072]
[65]
Eggemann, H.; Altmann, U.; Costa, S.D.; Ignatov, A. Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer. J. Cancer Res. Clin. Oncol., 2018, 144(2), 337-341.
[http://dx.doi.org/10.1007/s00432-017-2539-7] [PMID: 29098396]
[66]
Fentiman, I.S. The endocrinology of male breast cancer. Endocr. Relat. Cancer, 2018, 25(6), R365-R373.
[http://dx.doi.org/10.1530/ERC-18-0117] [PMID: 29752333]
[67]
Visram, H.; Kanji, F.; Dent, S.F. Endocrine therapy for male breast cancer: Rates of toxicity and adherence. Curr. Oncol., 2010, 17(5), 17-21.
[http://dx.doi.org/10.3747/co.v17i5.631] [PMID: 20975874]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy